SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

Dulaglutide decreases estimated glomerular filtration rate (eGFR) and proteinuria among youth with type 2 diabetes, according to the results of a study published in Diabetes Care.

Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes ...

The FDA approved Eli Lilly’s dulaglutide (Trulicity) for the reduction of major adverse cardiovascular events in adults with type 2 diabetes (T2D), with and without established cardiovascular ...

Adults with type 2 diabetes and mild to moderate chronic kidney disease assigned the once-weekly GLP-1 receptor agonist dulaglutide experienced a similar reduction in HbA1c vs. those assigned ...

Treatment with dulaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, was found to produce glycemic control similar to that of insulin glargine in patients with type 2 ...

In combination with metformin, advantages and disadvantages of Dulaglutide in type 2 diabetes are balanced, reviewers have concluded.

Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type 2 diabetes. The German Institute for Quality and Efficiency in Health Care ...